ํ๋ชจํฐ๋
ํ๋ชจํฐ๋์ ๊ฐ๋ ฅํ๊ณ ์ง์ ์๊ฐ์ด ๊ธด ํ์คํ๋ฏผ H2 ์์ฉ์ฒด ๊ธธํญ์ ๋ก, ์์ํ์์ ์์ฐ ๋ถ๋น๋ฅผ ์ต์ ํ๊ณ ์/์ญ์ด์ง์ฅ ๊ถค์, ์์ผ ๋ฐ ์๋์ผ์ ์น๋ฃํ๊ฑฐ๋ ์๋ฐฉํ๋ ๋ฐ ๋๋ฆฌ ์ฌ์ฉ๋ฉ๋๋ค. ์๋ฉํฐ๋๊ณผ ๋น๊ตํ ๋ ํ๋ชจํฐ๋์ ํจ์ฌ ๊ฐ๋ ฅํ๊ณ ํฌ์ฌ ๋น๋๊ฐ ์ ์ผ๋ฉฐ, ๊ฐ์ฅ ์ค์ํ ์ ์ **๊ฐ์ ์ฌ์ดํ ํฌ๋กฌ P450 ํจ์๊ณ๋ฅผ ์ต์ ํ์ง ์์** ํํ ์ฝ๋ฌผ ์ํธ์์ฉ์ด ๊ฑฐ์ ์๋ค๋ ๊ฒ์ ๋๋ค. > **์์ ์์ :** ๊ฒฝ๋ฏธํ ์์ฐ ์ต์ ๋ ์ผ์์ ์ธ ์๋ฐฉ์๋ ํจ๊ณผ์ ์ด์ง๋ง, ํ๋์ฑ ๊ถค์ ์น๋ฃ, ์ด๋ ์ ๋ฐ์ฑ ์์ผ ์๋ฐฉ ๋๋ ์ค์ฆ ์๋์ผ ๊ด๋ฆฌ์๋ ์ค๋ฉํ๋ผ์กธ๊ณผ ๊ฐ์ ์์ฑ์ ํํ ์ต์ ์ (PPI)๊ฐ ์ผ๋ฐ์ ์ผ๋ก ๋ ์ฐ์ํ๋ค๊ณ ๊ฐ์ฃผ๋ฉ๋๋ค. ๋ํ, ๊ฐ์ ๊ณ ์์ด์์ 3~14์ผ ๋์ ์ง์์ ์ผ๋ก ์ฌ์ฉํ๋ฉด ์ฝ๋ฆฌํ์ ๋ด์ฑ(**์์ฑ๋ด์ฑ, Tachyphylaxis**)์ด ๋ฐ์ํ๊ธฐ ์ฌ์ ์๊ฐ์ด ์ง๋จ์ ๋ฐ๋ผ ์์ฐ ์ต์ ํจ๋ฅ์ด ๊ฐ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : Famotidine acts as a competitive, reversible antagonist at the **H2 receptors** located on the basolateral membrane of gastric **parietal cells**. By blocking histamine binding, it prevents the activation of adenylate cyclase โ decreases intracellular cAMP levels โ reduces the activation of the **H+/K+-ATPase proton pump**. This effectively blunts both basal gastric acid secretion and secretion stimulated by food, pentagastrin, or insulin. By decreasing the total volume of gastric juice produced, H2-blockers also indirectly decrease the amount of pepsin secreted. It does not alter gastric emptying time, biliary secretion, or lower esophageal sphincter pressure.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- To reduce gastric acid production ยท 0.2 mg/kg ยท PO, SC, IM, IV ยท q24h ยท See warning about IV use in cats
- To reduce gastric acid production ยท 0.5 mg/kg ยท PO, SC, IM, IV ยท q12-24h
- For esophagitis ยท 0.5 mg/kg ยท PO ยท q12h
- For acute reflex esophagitis ยท 0.55-1.1 mg/kg ยท PO ยท q24h (or q12h if severe) ยท 2-3 weeks
- Adjunctive treatment of GI effects associated with chronic progressive renal disease ยท 1 mg/kg ยท PO ยท q24h
- Adjunctive treatment of GI effects associated with chronic progressive renal disease ยท 0.5-1 mg/kg ยท PO ยท q12-24h
- All uses (ulcers, gastritis, oesophagitis, hypersecretory conditions) ยท 0.5-1.0 mg/kg ยท PO ยท q12-24h ยท Effect on gastric pH diminishes with time when given daily.
- For stress induced ulcers ยท 0.25-0.5 mg/kg ยท PO, IV ยท q24h
- In combination with antibiotics for Helicobacter treatment ยท 0.25-0.5 mg/kg ยท PO, IV ยท q24h
- As an adjunct in ulcer treatment ยท 0.23 mg/kg or 0.35 mg/kg ยท IV ยท q8h (for 0.23 mg/kg) or q12h (for 0.35 mg/kg) ยท ARCI UCGFS Class 5 Drug
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity to H2 blockers
- Known hypersensitivity to famotidine or other H2 receptor antagonists
์ด์๋ฐ์
- Bradycardia (if infused too rapidly IV)
- GI effects (anorexia, vomiting, diarrhea)
- Headache
- Dry mouth or skin
- Intravascular hemolysis (rare, anecdotally reported in cats given IV)
- Transient increase in serum gastrin (returns to baseline by 14 days)
- Generally has a very good safety profile with fewer side effects than cimetidine
์ฝ๋ฌผ ์ํธ์์ฉ
- Azole Antifungals (ketoconazole, itraconazole, fluconazole) ยท Famotidine raises gastric pH, which may decrease the absorption of these agents. Administer the azole one hour prior to famotidine.
- Cefpodoxime, Cefuroxime ยท Famotidine may decrease the absorption of these cephalosporins. Taking with food may alleviate this effect.
- Iron Salts (Oral) ยท Famotidine may decrease the absorption of oral iron. Administer iron at least one hour prior to famotidine.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (decrease in symptomatology, endoscopic examination, resolution of blood in feces)
- Adverse effects
- Clinical signs of GI ulceration or bleeding (vomiting, melena, anorexia)
- Gastric pH (if clinically indicated and feasible)
๊ณผ์ฉ๋
Famotidine has a wide margin of safety. The minimum acute lethal dose in dogs is reported to be >2 grams/kg for oral doses and approximately 300 mg/kg for intravenous doses. IV doses in dogs ranging from 5-200 mg/kg caused vomiting, restlessness, mucous membrane pallor, and redness of the mouth and ears. Higher doses caused hypotension, tachycardia, and collapse. Most overdoses require only monitoring. In massive oral overdoses, gut-emptying protocols should be considered and supportive therapy initiated when warranted.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.